Table 1 Demographic and clinicopathologic characteristics of the study cohort prior to transplantation. Data are shown as mean ± SD. ALT, antilymphocyte globulin; ATG, anti-thymocyte globulin; BMI, body mass index; CMV, cytomegalovirus; D+, donor positive; R+ recipient positive; HbA1c, glycated hemoglobin; HD, hemodialysis; IL-2 RA, Interleukin-2 receptor antagonist; PD, peritoneal dialysis; SPKT, simultaneous pancreas-kidney transplantation
Variables | HD (N = 64) | PD (N = 19) | P-value |
|---|---|---|---|
Recipient | |||
 Age, years | 43.8 ± 9.1 | 43.2 ± 9.7 | 0.845 |
Gender | |||
  Male | 40 (62. 5%) | 6 (31.6%) | 0.017 |
  Female | 24 (37.5%) | 13 (68.4%) | |
 BMI, kg/m2 | 25.8 ± 4.4 | 24 ± 3.6 | 0.105 |
 Duration diabetes mellitus, years | 27.1 ± 8.4 | 26.1 ± 8.6 | 0.685 |
 Time on dialysis, months | 30.5 ± 21.3 | 27.0 ± 22.1 | 0.536 |
 HbA1c pre-transplantation, % | 7.7 ± 1.8 | 7.7 ± 1.2 | 0.940 |
 Time on waiting list, months | 10.9 ± 13.6 | 7.2 ± 6.9 | 0.242 |
Comorbidities | |||
  Diabetic retinopathy | 56 (87.5%) | 13 (68.4%) | 0.050 |
  Diabetic neuropathy | 39 (60.9%) | 11 (57.9%) | 0.812 |
  Arterial obstructive disease | 12 (18.8%) | 2 (10.5%) | 0.401 |
  Coronary heart disease | 21 (32.8%) | 2 (10.5%) | 0.050 |
  Depression | 21 (32.8%) | 2 (10.5%) | 0.049 |
 Taking aspirin pre-SPKT | 23 (35.9%) | 9 (47.4%) | 0.367 |
Donor | |||
 Age, years | 24.1 ± 11.8 | 19.2 ± 7.8 | 0.109 |
Gender | |||
  Male | 37 (57.8%) | 14 (73.3%) | 0.212 |
  Female | 27 (42.2%) | 5 (26.3%) | |
 BMI, kg/m2 | 22.4 ± 3.1 | 22.1 ± 2.8 | 0.987 |
Graft | |||
 Kidney cold ischemia, hours | 11.0 ± 3.3 | 11.1 ± 2.6 | 0.978 |
 Pancreas cold ischemia, hours | 10.1 ± 1.9 | 10.9 ± 3.9 | 0.294 |
CMV status | |||
 CMV D + | 31 (48.4%) | 11 (64.7%) | 0.211 |
 CMV R + | 36 (56.3%) | 13 (68.4%) | 0.343 |
Induction Therapy | |||
 ALG/ ATG | 54 (84.4%) | 15 (78.9%) | 0.864 |
 IL2-RA | 7 (10.9%) | 3 (15.8%) | 0.568 |
 None | 3 (4.7%) | 1 (5.3%) | 0.916 |